| 摘要 |
A pharmaceutical composition comprises (i) an anti-cancer agent; and (ii) a mitochondrial division inhibitor optionally together with one or more pharmaceutically acceptable carriers, diluents or excipients. The anti-cancer agent may be an anthracycline-based antibiotic selected from the group consisting of doxorubicin, daunorubicin, epirubicin, idarubicin or valrubicin. The anti-cancer agent may a variant, derivative or analogue of an anthracycline-based antibiotic, in particular, an anthracenedione, such as mitoxantrone. The anti-cancer agent may be tyrosine kinase inhibitor selected from the group consisting of erlotinib, gefitinib, imatinib and sunitinib. Preferably the mitochondrial division inhibitor is a cell-permeable quinazolinone compound capable of inhibiting mitochondrial cell division, in particular mdivi-1 (3-​(2,4-​Dichloro-​5-​methoxyphenyl)​-​2-​sulfanyl-​4(3H)​-​quinazolinone), or a variant, derivative or analogue thereof. Preferably the composition is for use in the treatment of cancer. The co-treatment of doxorubicin with mdivi-1 is provided. |
